Filing Flows

Filing Flows › Companies › Zevra Therapeutics › Cash flow

Zevra Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$9.8M in Q3 2026 · $38.3M over twelve months

Operating cash flow$10.0M
Capital spending−$238K
Free cash flow+$9.8M
Cash / net income0.5×

Analysis

In Q3 2026, Zevra Therapeutics generated $10.0M of operating cash flow and spent $238K on capital projects, leaving free cash flow of $9.8M. That is $5.7M more than in Q3 2025 ($4.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was $38.7M; the largest uses were net borrowing (+) / repaid (−) ($60.1M), capital spending ($459K), asset & business sales ($141K); besides operations, cash came from other investing ($77.0M), other financing ($13.0M); the cash balance rose by $67.7M.

Operating cash flow was $10.0M against net income of $19.2M — 0.5× profit, less cash than reported earnings, worth checking against working capital. The largest differences: stock-based pay +$2.7M, prepaid and other assets −$2.5M, receivables +$1.7M.

Free cash flow

Zevra Therapeutics: free cash flow by quarterZevra Therapeutics: free cash flow by quarter−$16.2MQ4 2024−$8.3MQ1 2025−$3.8MQ2 2025$4.2MQ3 2025$5.5MQ4 2025$6.1MQ1 2026$16.8MQ2 2026$9.8MQ3 2026
Operating cash flow less capital spending.
Zevra Therapeutics: operating cash flow against capital spendingZevra Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$16.2M$0Q4 2024−$8.2M$99KQ1 2025−$3.6M$213KQ2 2025$4.7M$554KQ3 2025$5.5M−$31KQ4 2025$6.1M$35KQ1 2026$17.0M$217KQ2 2026$10.0M$238KQ3 2026
Latest (Q3 2026): Operating cash flow $10.0M, Capital spending $238K.

Capital allocation, year by year

Zevra Therapeutics: where the cash came from (up) and went (down), by fiscal yearZevra Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $10.4MFY2021: Net borrowing −$38.1MFY2021: Capital spending −$102KFY2021: Buybacks −$2.8M$10.4MFY2021FY2022: Operating cash flow −$18.7MFY2022: Net borrowing $12.8MFY2022: Shares issued $324KFY2022: Capital spending −$93KFY2022: Acquisitions −$14.1MFY2022: Buybacks −$4.7M$13.1MFY2022FY2023: Operating cash flow −$33.5MFY2023: Net borrowing $24.9MFY2023: Shares issued $6.1MFY2023: Capital spending −$296KFY2023: Acquisitions −$30.4MFY2023: Buybacks −$3.4M$31.0MFY2023FY2024: Operating cash flow −$69.7MFY2024: Net borrowing $16.3MFY2024: Shares issued $66.2M$82.5MFY2024FY2025: Operating cash flow −$1.6MFY2025: Shares issued $3.2MFY2025: Asset sales $448KFY2025: Capital spending −$835K$3.6MFY2025
Over these 5 years operating cash flow totalled −$113M; the largest uses were operating cash flow ($124M) and acquisitions ($44.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$196M
Debt$61.9M
Net cash$134M

Zevra Therapeutics funds itself: free cash flow was $38.3M over the last twelve months, and $196M of cash and investments stands against $61.9M of debt.

Where the cash came from and went

Zevra Therapeutics: sources (+) and uses (−) of cash, Q3 2026Zevra Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other investing−$34.6MCash drawn (+) / kept (−)$23.2MOperating cash flow$10.0MShares issued$1.6MCapital spending−$238KExchange rates$80KTaxes on employees’ shares−$29K
Zevra Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Zevra Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing$77.0MCash drawn (+) / kept (−)−$67.7MNet borrowing (+) / repaid (−)−$60.1MOperating cash flow$38.7MOther financing$13.0MCapital spending−$459KExchange rates−$351KAsset & business sales−$141K

From profit to cash

Zevra Therapeutics: net income to operating cash flow, Q3 2026Zevra Therapeutics: net income to operating cash flow, Q3 2026Net income$19.2MDepreciation & amortization$378KStock-based pay$2.7MReceivables$1.7MInventory−$637KPayables−$338KPrepaid and other assets−$2.5MOther liabilities$383KOperating cash flow$10.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$10.0M−$238K—$1.6M$23.2M$9.8M
Q2 2026$17.0M−$217K—$1K−$49.7M$16.8M
Q1 2026$6.1M−$35K−$60.1M$752K−$33.2M$6.1M
Q4 2025$5.5M$31K——−$8.0M$5.5M
Q3 2025$4.7M−$554K—$573K−$6.7M$4.2M
Q2 2025−$3.6M−$213K—$968K−$10.4M−$3.8M
Q1 2025−$8.2M−$99K—$2.0M−$3.6M−$8.3M
Q4 2024−$16.2M——$415K$20.3M−$16.2M

Zevra Therapeutics: income statement and cash flow

Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%. The chart follows the revenue to costs, profit and cash.

Zevra Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.